This investigation is the first to assess the efficacy of the sEH inhibitor TPPU, a well-established lipidome-modifying agent, against acute cSiO2-triggered lung inflammation, pulmonary fibrosis, and early autoimmunity in lupus-prone mice. Here, EPHX2 is linked to pulmonary fibrosis.